Biotime Inc (BTX) 5.72 $BTX
First Week of BTX December 18th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:04AM CDT
Investors in BioTime, Inc. saw new options become available this week, for the December 18th expiration.
BTX: 5.72 (-0.16)
BioTime Licenses Beckman Research Institute of City of Hope to Manufacture Clinical Grade Stem Cells
Business Wire - Wed Apr 22, 7:00AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime's subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA) through which ESI's clinical-grade human embryonic stem (hES) cells will be manufactured and provided to BRICOH's clinical collaborators, including medical research organizations intent on using the hES cells to develop and commercialize therapeutic products to treat human disease. The Agreement is a critical part of BioTime's strategy to leverage third party funding and generate future revenues by placing its hES cells in programs developing a wide array of therapeutic applications made possible with pluripotent stem cell technology, products that are currently not being developed by BioTime or its subsidiaries. Successful medical research organizations will need to obtain separate licenses from BioTime in order to advance their products based on ESI's hES cells into clinical trials and commercialization. Those licenses may entitle BioTime to receive additional revenues such as milestone payments related to the attainment of clinical trial and commercial milestones and royalties on product sales. BioTime and BioTime subsidiaries will retain the rights to manufacture their own stem cell-based products as well as to license rights to other third parties.
BTX: 5.72 (-0.16)
50.6% Return Seen to Date on SmarTrend Biotime Call (BTX)
Comtex SmarTrend(R) - Mon Apr 20, 4:51PM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 50.57% as of today's recent price of $5.24.
BTX: 5.72 (-0.16)
OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers
Business Wire - Mon Apr 20, 11:00AM CDT
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx(TM), OncoCyte's non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The clinical data was presented by Maria Prendes, PhD, Director of Manufacturing at OncoCyte, at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 8:00 AM -12:00 PM EDT on Monday, April 20, 2015.
BTX: 5.72 (-0.16)
Positive Clinical Results of OncoCyte's PanC-Dx(TM) Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer
Business Wire - Mon Apr 20, 5:30AM CDT
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced positive clinical results of PanC-Dx(TM), OncoCyte's class of proprietary, non-invasive cancer diagnostic tests, in detecting the most common type of bladder cancer, urothelial carcinoma (UC). Karen B. Chapman, PhD, Vice President of Research at OncoCyte, presented the results from two prospective clinical studies of PanC-Dx(TM) at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 1:00 PM - 5:00 PM EDT on Sunday, April 19, 2015.
BTX: 5.72 (-0.16)
Shares of BTX Up 63.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 13, 11:14AM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 63.79% as of today's recent price of $5.70.
BTX: 5.72 (-0.16)
Shares of BTX Up 44.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 06, 9:48AM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 43.97% as of today's recent price of $5.01.
BTX: 5.72 (-0.16)
BioTime launches pilot program for COPD smartphone app
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 9:40AM CDT
BTX: 5.72 (-0.16)
LifeMap Solutions and Mount Sinai - National Jewish Health Respiratory Institute Launch Pilot Program of COPD Navigator App
Business Wire - Tue Mar 31, 8:00AM CDT
LifeMap Solutions, an emerging digital therapeutics provider and subsidiary of BioTime, Inc. (NYSE MKT: BTX), today launched a pilot program for COPD Navigator, an Apple HealthKit-compliant iOS app that helps patients monitor and manage the symptoms of COPD. Developed in close partnership with researchers from the Icahn School of Medicine at Mount Sinai and with COPD experts from the Mount Sinai - National Jewish Health Respiratory Institute, COPD Navigator harnesses the power of mHealth (mobile health) technology and big data analysis to provide COPD patients with an engaging, interactive coach in their pocket. A patient's doctor specifies the app's settings and communications. During the pilot program, physicians at The Respiratory Institute will work with patients who use the COPD Navigator iPhone app with the goal of improving their self-management of COPD.
BTX: 5.72 (-0.16)
Biotime Has Returned 45.1% Since SmarTrend Recommendation (BTX)
Comtex SmarTrend(R) - Mon Mar 23, 5:04PM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 45.11% as of today's recent price of $5.05.
BTX: 5.72 (-0.16)
OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx(TM) Cancer Diagnostic in Bladder and Breast Cancer
Business Wire - Fri Mar 20, 7:00AM CDT
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the online availability of abstracts providing human clinical data highlighting the potential of PanC-Dx(TM), OncoCyte's class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers. These markers were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers, including COL10A1, are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte. Data included in the abstracts will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015.
BTX: 5.72 (-0.16)
Investors appear to wake up to potential of BioTime's Asthma iPhone app
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:04PM CDT
BTX: 5.72 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 11:47AM CDT
APPS: 3.83 (-0.06), RMGN: 1.61 (+0.09), GOMO: 5.05 (+0.06), MILL: 0.98 (unch), HIIQ: 7.55 (-0.02), DGSE: 1.47 (-0.02), VNCE: 18.94 (-0.30), BIOC: 2.88 (-0.22), GBR: 2.16 (-0.16), GES: 18.72 (+0.27), SFY: 2.91 (-0.07), CNDO: 3.97 (-0.14), BTX: 5.72 (-0.16), JUNO: 56.66 (-1.06), MTOR: 12.53 (+0.05), VBLT: 4.23 (+0.07), WHLR: 2.34 (unch), CMLS: 2.43 (-0.03), AMCO: 1.09 (+0.04), FOLD: 12.25 (-0.05)
BioTime ups revenues 18% in FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 8:21AM CDT
BTX: 5.72 (-0.16)
BioTime reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 7:11AM CDT
BTX: 5.72 (-0.16)
BioTime, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments
Business Wire - Wed Mar 11, 7:00AM CDT
BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the quarter and year ended December 31, 2014, and highlighted its fourth quarter and recent corporate accomplishments.
BTX: 5.72 (-0.16)
Icahn School of Medicine at Mount Sinai and LifeMap Solutions Launch Asthma Study for iPhone
Business Wire - Mon Mar 09, 1:48PM CDT
The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a subsidiary of BioTime (NYSE MKT:BTX), today announced the launch of a large-scale medical research study that uses the new ResearchKit framework developed by Apple to make it easy for individuals who suffer from asthma to participate in studies right from their iPhone.
BTX: 5.72 (-0.16)
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
Business Wire - Tue Feb 17, 7:45AM CST
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. ("Cell Cure"
today provided an update on Cell Cure's product development and partnering activities.
BTX: 5.72 (-0.16)
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock
PR Newswire - Tue Feb 10, 2:00PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company", a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock.
BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
First Week of BTX December 18th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:04AM CDT
Investors in BioTime, Inc. saw new options become available this week, for the December 18th expiration.
BTX: 5.72 (-0.16)
BioTime Licenses Beckman Research Institute of City of Hope to Manufacture Clinical Grade Stem Cells
Business Wire - Wed Apr 22, 7:00AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced a nonexclusive License Agreement between BioTime's subsidiary ES Cell International Pte Ltd (ESI) and Beckman Research Institute of the City of Hope (BRICOH, Duarte, CA) through which ESI's clinical-grade human embryonic stem (hES) cells will be manufactured and provided to BRICOH's clinical collaborators, including medical research organizations intent on using the hES cells to develop and commercialize therapeutic products to treat human disease. The Agreement is a critical part of BioTime's strategy to leverage third party funding and generate future revenues by placing its hES cells in programs developing a wide array of therapeutic applications made possible with pluripotent stem cell technology, products that are currently not being developed by BioTime or its subsidiaries. Successful medical research organizations will need to obtain separate licenses from BioTime in order to advance their products based on ESI's hES cells into clinical trials and commercialization. Those licenses may entitle BioTime to receive additional revenues such as milestone payments related to the attainment of clinical trial and commercial milestones and royalties on product sales. BioTime and BioTime subsidiaries will retain the rights to manufacture their own stem cell-based products as well as to license rights to other third parties.
BTX: 5.72 (-0.16)
50.6% Return Seen to Date on SmarTrend Biotime Call (BTX)
Comtex SmarTrend(R) - Mon Apr 20, 4:51PM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 50.57% as of today's recent price of $5.24.
BTX: 5.72 (-0.16)
OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers
Business Wire - Mon Apr 20, 11:00AM CDT
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx(TM), OncoCyte's non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The clinical data was presented by Maria Prendes, PhD, Director of Manufacturing at OncoCyte, at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 8:00 AM -12:00 PM EDT on Monday, April 20, 2015.
BTX: 5.72 (-0.16)
Positive Clinical Results of OncoCyte's PanC-Dx(TM) Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer
Business Wire - Mon Apr 20, 5:30AM CDT
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced positive clinical results of PanC-Dx(TM), OncoCyte's class of proprietary, non-invasive cancer diagnostic tests, in detecting the most common type of bladder cancer, urothelial carcinoma (UC). Karen B. Chapman, PhD, Vice President of Research at OncoCyte, presented the results from two prospective clinical studies of PanC-Dx(TM) at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 1:00 PM - 5:00 PM EDT on Sunday, April 19, 2015.
BTX: 5.72 (-0.16)
Shares of BTX Up 63.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 13, 11:14AM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 63.79% as of today's recent price of $5.70.
BTX: 5.72 (-0.16)
Shares of BTX Up 44.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 06, 9:48AM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 43.97% as of today's recent price of $5.01.
BTX: 5.72 (-0.16)
BioTime launches pilot program for COPD smartphone app
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 9:40AM CDT
BTX: 5.72 (-0.16)
LifeMap Solutions and Mount Sinai - National Jewish Health Respiratory Institute Launch Pilot Program of COPD Navigator App
Business Wire - Tue Mar 31, 8:00AM CDT
LifeMap Solutions, an emerging digital therapeutics provider and subsidiary of BioTime, Inc. (NYSE MKT: BTX), today launched a pilot program for COPD Navigator, an Apple HealthKit-compliant iOS app that helps patients monitor and manage the symptoms of COPD. Developed in close partnership with researchers from the Icahn School of Medicine at Mount Sinai and with COPD experts from the Mount Sinai - National Jewish Health Respiratory Institute, COPD Navigator harnesses the power of mHealth (mobile health) technology and big data analysis to provide COPD patients with an engaging, interactive coach in their pocket. A patient's doctor specifies the app's settings and communications. During the pilot program, physicians at The Respiratory Institute will work with patients who use the COPD Navigator iPhone app with the goal of improving their self-management of COPD.
BTX: 5.72 (-0.16)
Biotime Has Returned 45.1% Since SmarTrend Recommendation (BTX)
Comtex SmarTrend(R) - Mon Mar 23, 5:04PM CDT
SmarTrend identified an Uptrend for Biotime (NYSE:BTX) on September 9th, 2014 at $3.48. In approximately 7 months, Biotime has returned 45.11% as of today's recent price of $5.05.
BTX: 5.72 (-0.16)
OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx(TM) Cancer Diagnostic in Bladder and Breast Cancer
Business Wire - Fri Mar 20, 7:00AM CDT
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced the online availability of abstracts providing human clinical data highlighting the potential of PanC-Dx(TM), OncoCyte's class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers. These markers were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers, including COL10A1, are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte. Data included in the abstracts will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015.
BTX: 5.72 (-0.16)
Investors appear to wake up to potential of BioTime's Asthma iPhone app
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:04PM CDT
BTX: 5.72 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 11:47AM CDT
APPS: 3.83 (-0.06), RMGN: 1.61 (+0.09), GOMO: 5.05 (+0.06), MILL: 0.98 (unch), HIIQ: 7.55 (-0.02), DGSE: 1.47 (-0.02), VNCE: 18.94 (-0.30), BIOC: 2.88 (-0.22), GBR: 2.16 (-0.16), GES: 18.72 (+0.27), SFY: 2.91 (-0.07), CNDO: 3.97 (-0.14), BTX: 5.72 (-0.16), JUNO: 56.66 (-1.06), MTOR: 12.53 (+0.05), VBLT: 4.23 (+0.07), WHLR: 2.34 (unch), CMLS: 2.43 (-0.03), AMCO: 1.09 (+0.04), FOLD: 12.25 (-0.05)
BioTime ups revenues 18% in FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 8:21AM CDT
BTX: 5.72 (-0.16)
BioTime reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 7:11AM CDT
BTX: 5.72 (-0.16)
BioTime, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments
Business Wire - Wed Mar 11, 7:00AM CDT
BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the quarter and year ended December 31, 2014, and highlighted its fourth quarter and recent corporate accomplishments.
BTX: 5.72 (-0.16)
Icahn School of Medicine at Mount Sinai and LifeMap Solutions Launch Asthma Study for iPhone
Business Wire - Mon Mar 09, 1:48PM CDT
The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a subsidiary of BioTime (NYSE MKT:BTX), today announced the launch of a large-scale medical research study that uses the new ResearchKit framework developed by Apple to make it easy for individuals who suffer from asthma to participate in studies right from their iPhone.
BTX: 5.72 (-0.16)
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities
Business Wire - Tue Feb 17, 7:45AM CST
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. ("Cell Cure"
today provided an update on Cell Cure's product development and partnering activities. BTX: 5.72 (-0.16)
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock
PR Newswire - Tue Feb 10, 2:00PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock. BTX: 5.72 (-0.16), AST: 14.77 (+0.66)
